Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2014

Open Access 01-12-2014 | Research article

Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and Harmonized criteria

Authors: Daya Ram Pokharel, Dipendra Khadka, Manoj Sigdel, Naval Kishor Yadav, Shreedhar Acharya, Ram Chandra Kafle, Pramod Shankar Shukla

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2014

Login to get access

Abstract

Background

Metabolic syndrome (MetS) present in type 2 diabetic patients greatly increases the risk of strokes and cardiovascular diseases. Timely detection and mapping of MetS facilitates appropriate preventive and therapeutic approaches to minimize these risks. Our study aimed to determine the prevalence of MetS among Nepalese type 2 diabetic patients using WHO (1999), NCEP ATP III (2001), IDF (2005) and Harmonized (2009) definitions and identify the diagnostic concordance and disparity resulting from these four definitions.

Methods

Clinical and biochemical data were collected for 1061 type 2 diabetic patients at Manipal Teaching Hospital, Pokhara, Nepal. The data was analyzed in order to identify prevalence of MetS in these patients. Statistical analysis included usage of Student’s t- and Chi-square tests, kappa statistics and 95% confidence intervals.

Results

The total age adjusted prevalence rates of MetS were 80.3%, 73.9%, 69.9% and 66.8% according to Harmonized, NCEP ATP III, WHO and IDF definitions, respectively. Prevalence increased with the age and was higher in females (p <0.001) according to WHO, NCEP ATP III and Harmonized definitions. Patients of Dalit community had the highest prevalence (p<0.05) according to NCEP ATP III and Harmonized definitions while Mongoloid and Newar patients had the highest prevalence (p <0.05) according to WHO and IDF definitions, respectively. Prevalence was also highest among patient engaged in agriculture occupation. Central obesity and hypertension were respectively the most and the least prevalent components of MetS. The highest overall agreement was between Harmonized and NCEP ATP III definitions (k =0.62, substantial) and the lowest between WHO & IDF definitions (k=0.26, slight). The Harmonized definition had the highest sensitivity (99.9%) and negative predictive value (98.9%) while NCEP ATP III definition had the highest specificity (98.9%) and positive predictive values (99.9%) in identifying the cases of MetS.

Conclusions

The prevalence of MetS among Nepalese type 2 diabetic patients was very high suggesting that these patients were at increased risk of strokes, cardiovascular diseases and premature death. The Harmonized definition was the most sensitive while NCEP ATP III and IDF definitions were the most specific in detecting the presence of MetS in Nepalese type 2 diabetic patients.
Literature
1.
2.
go back to reference Reaven G: Metabolic syndrome: pathophysiology and implications for management of cardiovascular diseases. Circulation 2002, 106: 286–288. 10.1161/01.CIR.0000019884.36724.D9CrossRefPubMed Reaven G: Metabolic syndrome: pathophysiology and implications for management of cardiovascular diseases. Circulation 2002, 106: 286–288. 10.1161/01.CIR.0000019884.36724.D9CrossRefPubMed
3.
go back to reference Lindsay RS, Howard BV: Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep 2004, 4: 63–68. 10.1007/s11892-004-0013-9CrossRefPubMed Lindsay RS, Howard BV: Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep 2004, 4: 63–68. 10.1007/s11892-004-0013-9CrossRefPubMed
4.
go back to reference Hanley AJ, Festa A, D’Agostino RB Jr, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM: Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 2004, 53: 1773–1781. 10.2337/diabetes.53.7.1773CrossRefPubMed Hanley AJ, Festa A, D’Agostino RB Jr, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM: Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 2004, 53: 1773–1781. 10.2337/diabetes.53.7.1773CrossRefPubMed
5.
go back to reference Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15: 539–553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-SCrossRefPubMed Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15: 539–553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-SCrossRefPubMed
6.
go back to reference Expert Panel on Detection, Evaluation and Treatment of High BloodCholesterol in Adults (Adult Treatment Panel III): Executive summary of the third report of the national cholesterol education program (NCEP) JAMA 2001, 285: 2486–2497. 10.1001/jama.285.19.2486CrossRef Expert Panel on Detection, Evaluation and Treatment of High BloodCholesterol in Adults (Adult Treatment Panel III): Executive summary of the third report of the national cholesterol education program (NCEP) JAMA 2001, 285: 2486–2497. 10.1001/jama.285.19.2486CrossRef
7.
go back to reference Alberti KG, Zimmet P, Shaw J: IDF epidemiology task force consensus group. The metabolic syndrome: a new worldwide definition. Lancet 2005, 366: 1059–1062. 10.1016/S0140-6736(05)67402-8CrossRefPubMed Alberti KG, Zimmet P, Shaw J: IDF epidemiology task force consensus group. The metabolic syndrome: a new worldwide definition. Lancet 2005, 366: 1059–1062. 10.1016/S0140-6736(05)67402-8CrossRefPubMed
8.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA: Harmonizing the metabolic syndrome. A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and International association for the study of obesity. Circulation 2009, 120: 1640–1645. 10.1161/CIRCULATIONAHA.109.192644CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA: Harmonizing the metabolic syndrome. A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and International association for the study of obesity. Circulation 2009, 120: 1640–1645. 10.1161/CIRCULATIONAHA.109.192644CrossRefPubMed
9.
go back to reference Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87: 4–14. 10.1016/j.diabres.2009.10.007CrossRefPubMed Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87: 4–14. 10.1016/j.diabres.2009.10.007CrossRefPubMed
10.
go back to reference Jayawardena R, Ranasinghe P, Byrne NM, Soares MJ, Katulanda P, Andrew P, Hills AP: Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis. BMC Public Health 2012, 12: 380. 10.1186/1471-2458-12-380CrossRefPubMedPubMedCentral Jayawardena R, Ranasinghe P, Byrne NM, Soares MJ, Katulanda P, Andrew P, Hills AP: Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis. BMC Public Health 2012, 12: 380. 10.1186/1471-2458-12-380CrossRefPubMedPubMedCentral
11.
go back to reference Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52: 1210–1214. 10.2337/diabetes.52.5.1210CrossRefPubMed Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52: 1210–1214. 10.2337/diabetes.52.5.1210CrossRefPubMed
12.
go back to reference Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National cholesterol education program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio heart study. Circulation 2004, 110: 1251–1257. 10.1161/01.CIR.0000140762.04598.F9CrossRefPubMed Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National cholesterol education program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio heart study. Circulation 2004, 110: 1251–1257. 10.1161/01.CIR.0000140762.04598.F9CrossRefPubMed
13.
go back to reference Tong PC, Kong AP, So WY, Yang X, Ho CS, Ma RC, Ozaki R, Chow CC, Lam CW, Chan JC, Cockram CS: The usefulness of the International Diabetes Federation and the National Cholesterol Education Program’s Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007, 30: 1206–1211. 10.2337/dc06-1484CrossRefPubMed Tong PC, Kong AP, So WY, Yang X, Ho CS, Ma RC, Ozaki R, Chow CC, Lam CW, Chan JC, Cockram CS: The usefulness of the International Diabetes Federation and the National Cholesterol Education Program’s Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007, 30: 1206–1211. 10.2337/dc06-1484CrossRefPubMed
14.
go back to reference Protopsaltis I, Nikolopoulos G, Dimou E, Brestas P, Kokkoris S, Korantzopoulos P, Melidonis A: Metabolic syndrome and its components as predictors of all-cause mortality and coronary heart disease in type 2 diabetic patients. Atherosclerosis 2007, 195: 189–194. 10.1016/j.atherosclerosis.2006.09.019CrossRefPubMed Protopsaltis I, Nikolopoulos G, Dimou E, Brestas P, Kokkoris S, Korantzopoulos P, Melidonis A: Metabolic syndrome and its components as predictors of all-cause mortality and coronary heart disease in type 2 diabetic patients. Atherosclerosis 2007, 195: 189–194. 10.1016/j.atherosclerosis.2006.09.019CrossRefPubMed
15.
go back to reference Sharma SK, Ghimire A, Radhakrishnan J, Thapa L, Shrestha NR, Paudel N, Gurung KRM, Budathoki A, Baral N, Brodie D: Prevalence of hypertension, obesity, diabetes, and metabolic syndrome in Nepal. Int J Hypertens 2011, 2011: 821971. 10.4061/2011/821971CrossRefPubMedPubMedCentral Sharma SK, Ghimire A, Radhakrishnan J, Thapa L, Shrestha NR, Paudel N, Gurung KRM, Budathoki A, Baral N, Brodie D: Prevalence of hypertension, obesity, diabetes, and metabolic syndrome in Nepal. Int J Hypertens 2011, 2011: 821971. 10.4061/2011/821971CrossRefPubMedPubMedCentral
16.
go back to reference Shrestha R, Jha SC, Khanal M, Gyawali P, Yadav BK, Jha B: Association of cardiovascular risk factors in hypertensive subjects with metabolic syndrome defined by three different definitions. JNMA 2011, 51: 157–163. Shrestha R, Jha SC, Khanal M, Gyawali P, Yadav BK, Jha B: Association of cardiovascular risk factors in hypertensive subjects with metabolic syndrome defined by three different definitions. JNMA 2011, 51: 157–163.
17.
go back to reference Bhattarai S, Kohli SC, Sapkota S: Prevalence of metabolic syndrome in type 2 diabetes mellitus patients using NCEP/ATP III and IDF criteria in Nepal. Nepal J Med Sci 2012, 1: 79–83.CrossRef Bhattarai S, Kohli SC, Sapkota S: Prevalence of metabolic syndrome in type 2 diabetes mellitus patients using NCEP/ATP III and IDF criteria in Nepal. Nepal J Med Sci 2012, 1: 79–83.CrossRef
18.
go back to reference Tamang HK, Timilsina U, Thapa S, Singh KP, Shrestha S, Singh P, Shrestha B: Prevalence of metabolic syndrome among Nepalese type 2 diabetic patients. Nepal Med Coll J 2013, 15: 50–55.PubMed Tamang HK, Timilsina U, Thapa S, Singh KP, Shrestha S, Singh P, Shrestha B: Prevalence of metabolic syndrome among Nepalese type 2 diabetic patients. Nepal Med Coll J 2013, 15: 50–55.PubMed
19.
go back to reference World Health Organisation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006. World Health Organisation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006.
20.
go back to reference Asia-Pacific Steering Committee: The Asia-Pacific perspective: Redefining obesity and its treatment Health Communications Australia 2000. Asia-Pacific Steering Committee: The Asia-Pacific perspective: Redefining obesity and its treatment Health Communications Australia 2000.
21.
go back to reference Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499–502.CrossRefPubMed Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499–502.CrossRefPubMed
22.
go back to reference Keyfitz N: Sampling variance of standardized mortality rates. Human Biol 1966, 38: 309–317.PubMed Keyfitz N: Sampling variance of standardized mortality rates. Human Biol 1966, 38: 309–317.PubMed
23.
go back to reference Agresti A, Coull BA: Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 1998, 52: 119–126. Agresti A, Coull BA: Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 1998, 52: 119–126.
24.
go back to reference Central Bureau of Statistics, Government of Nepal: National Population and Housing Census 2011 (A national report). Kathmandu; 2012. Central Bureau of Statistics, Government of Nepal: National Population and Housing Census 2011 (A national report). Kathmandu; 2012.
25.
go back to reference Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977, 33: 159–174. 10.2307/2529310CrossRefPubMed Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977, 33: 159–174. 10.2307/2529310CrossRefPubMed
26.
go back to reference Deepa M, Farooq S, Datta M, Deepa R, Mohan V: Prevalence of metabolic syndrome using WHO, ATP III and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev 2007, 23: 127–134. 10.1002/dmrr.658CrossRefPubMed Deepa M, Farooq S, Datta M, Deepa R, Mohan V: Prevalence of metabolic syndrome using WHO, ATP III and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev 2007, 23: 127–134. 10.1002/dmrr.658CrossRefPubMed
27.
go back to reference Motala AA, Esterhuizen T, Pirie FJ, Omar MAK: The prevalence of metabolic syndrome and determination of the optimal waist circumference cut-off points in a rural South African community. Diabetes Care 2011, 34: 1032–1037. 10.2337/dc10-1921CrossRefPubMedPubMedCentral Motala AA, Esterhuizen T, Pirie FJ, Omar MAK: The prevalence of metabolic syndrome and determination of the optimal waist circumference cut-off points in a rural South African community. Diabetes Care 2011, 34: 1032–1037. 10.2337/dc10-1921CrossRefPubMedPubMedCentral
28.
go back to reference Katulanda P, Ranasinghe P, Jayawardana R, Sheriff R, Matthews DR: Metabolic syndrome among Sri Lankan adults: prevalence, patterns and correlates. Diabetol Metab Syndr 2012, 4: 24. 10.1186/1758-5996-4-24CrossRefPubMedPubMedCentral Katulanda P, Ranasinghe P, Jayawardana R, Sheriff R, Matthews DR: Metabolic syndrome among Sri Lankan adults: prevalence, patterns and correlates. Diabetol Metab Syndr 2012, 4: 24. 10.1186/1758-5996-4-24CrossRefPubMedPubMedCentral
30.
go back to reference Tan MC, Ng OC, Wong TW, Joseph A, Chan YM, Hejar AR: Prevalence of metabolic syndrome in type 2 diabetic patients: a comparative study using WHO, NCEP ATP III, IDF and Harmonized definitions. Health 2013, 5: 1689–1696. 10.4236/health.2013.510227CrossRef Tan MC, Ng OC, Wong TW, Joseph A, Chan YM, Hejar AR: Prevalence of metabolic syndrome in type 2 diabetic patients: a comparative study using WHO, NCEP ATP III, IDF and Harmonized definitions. Health 2013, 5: 1689–1696. 10.4236/health.2013.510227CrossRef
31.
go back to reference Kengne AP, Limen SN, Sobngwi E, Djouogo CFT, Nouedoui C: Metabolic syndrome in type 2 diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan Africans. Diabetol Metab Syndr 2012, 4: 22. 10.1186/1758-5996-4-22CrossRefPubMedPubMedCentral Kengne AP, Limen SN, Sobngwi E, Djouogo CFT, Nouedoui C: Metabolic syndrome in type 2 diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan Africans. Diabetol Metab Syndr 2012, 4: 22. 10.1186/1758-5996-4-22CrossRefPubMedPubMedCentral
32.
go back to reference Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE: The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract 2007, 77: 471–478. 10.1016/j.diabres.2007.02.002CrossRefPubMed Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE: The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract 2007, 77: 471–478. 10.1016/j.diabres.2007.02.002CrossRefPubMed
33.
go back to reference Niroula BP: Caste/ethnic composition of Nepal. CNAS J 1998, 25: 15–56. Niroula BP: Caste/ethnic composition of Nepal. CNAS J 1998, 25: 15–56.
34.
go back to reference Ardern CI, Katzmarzyk PT: Geographic and demographic variation in the prevalence of the metabolic syndrome in Canada. Can J Diabetes 2007, 31: 34–46. 10.1016/S1499-2671(07)11009-1CrossRef Ardern CI, Katzmarzyk PT: Geographic and demographic variation in the prevalence of the metabolic syndrome in Canada. Can J Diabetes 2007, 31: 34–46. 10.1016/S1499-2671(07)11009-1CrossRef
35.
go back to reference Santos AC, Ebrahim S, Barros H: Gender, socio-economic status and metabolic syndrome in middle-aged and old adults. BMC Public Health 2008, 8: 62. 10.1186/1471-2458-8-62CrossRefPubMedPubMedCentral Santos AC, Ebrahim S, Barros H: Gender, socio-economic status and metabolic syndrome in middle-aged and old adults. BMC Public Health 2008, 8: 62. 10.1186/1471-2458-8-62CrossRefPubMedPubMedCentral
36.
go back to reference Sánchez-Chaparro MA, Calvo-Bonacho E, González-Quintela A, Fernández-Labandera C, Cabrera M, Sáinz JC, Fernández-Meseguer A, Banegas JR, Ruilope LM, Valdivielso P, Román-García J: Occupation-related differences in the prevalence of metabolic syndrome. Diabetes Care 2008, 31: 1884–1885. 10.2337/dc08-0431CrossRefPubMedPubMedCentral Sánchez-Chaparro MA, Calvo-Bonacho E, González-Quintela A, Fernández-Labandera C, Cabrera M, Sáinz JC, Fernández-Meseguer A, Banegas JR, Ruilope LM, Valdivielso P, Román-García J: Occupation-related differences in the prevalence of metabolic syndrome. Diabetes Care 2008, 31: 1884–1885. 10.2337/dc08-0431CrossRefPubMedPubMedCentral
37.
go back to reference de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM, Resnick HE: Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: The strong heart study. Diabetes Care 2007, 30: 1851–1856. 10.2337/dc06-2152CrossRefPubMed de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM, Resnick HE: Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: The strong heart study. Diabetes Care 2007, 30: 1851–1856. 10.2337/dc06-2152CrossRefPubMed
38.
go back to reference Enas EA, Mohan V, Deepa M, Farooq S, Pazhoor S, Chennikkara H: Metabolic Syndrome among Asian Indians: A population with high rates of diabetes and premature heart disease. J Cardiometab Syndr 2007, 2: 267–275. 10.1111/j.1559-4564.2007.07392.xCrossRefPubMed Enas EA, Mohan V, Deepa M, Farooq S, Pazhoor S, Chennikkara H: Metabolic Syndrome among Asian Indians: A population with high rates of diabetes and premature heart disease. J Cardiometab Syndr 2007, 2: 267–275. 10.1111/j.1559-4564.2007.07392.xCrossRefPubMed
39.
go back to reference Ahmed A, Khan TE, Yasmeen T, Awan S, Islam N: Metabolic syndrome in type 2 diabetes: comparison of WHO, modified ATPIII & IDF criteria. J Pak Med Assoc 2012, 62: 574–579. Ahmed A, Khan TE, Yasmeen T, Awan S, Islam N: Metabolic syndrome in type 2 diabetes: comparison of WHO, modified ATPIII & IDF criteria. J Pak Med Assoc 2012, 62: 574–579.
40.
go back to reference Yadav D, Mahajan S, Subramanian SK, Bisen PS, Chung CH, Prasad GBKS: Prevalence of metabolic syndrome in type 2 diabetes mellitus using NCEP-ATPIII, IDF and WHO definition and its agreement in Gwalior Chambal Region of Central India. Global J Health Sci 2013, 5: 144–155. 10.5539/gjhs.v5n6p142CrossRef Yadav D, Mahajan S, Subramanian SK, Bisen PS, Chung CH, Prasad GBKS: Prevalence of metabolic syndrome in type 2 diabetes mellitus using NCEP-ATPIII, IDF and WHO definition and its agreement in Gwalior Chambal Region of Central India. Global J Health Sci 2013, 5: 144–155. 10.5539/gjhs.v5n6p142CrossRef
41.
Metadata
Title
Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and Harmonized criteria
Authors
Daya Ram Pokharel
Dipendra Khadka
Manoj Sigdel
Naval Kishor Yadav
Shreedhar Acharya
Ram Chandra Kafle
Pramod Shankar Shukla
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2014
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-014-0104-3

Other articles of this Issue 1/2014

Journal of Diabetes & Metabolic Disorders 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.